In summary, our findings demonstrate that Maritoclax, a selective MCL1 inhibitor, effectively overcomes FBW7 deficiency‐driven irinotecan resistance in CRC by targeting and degrading aberrantly accumulated MCL1. Here, FBXW7 is linked to colorectal carcinoma.